Abivax (NASDAQ:ABVX) Shares Down 3.4% Following Weak Earnings

Abivax SA Sponsored ADR (NASDAQ:ABVX)’s stock price dropped 3.4% during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings. The stock traded as low as $97.68 and last traded at $99.9150. Approximately 455,998 shares traded hands during trading, a decline of 68% from the average session volume of 1,419,077 shares. The stock had previously closed at $103.45.

The company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The business had revenue of $1.37 million during the quarter, compared to analyst estimates of $0.80 million.

More Abivax News

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: Abivax said it plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026. The company also reported €402.4 million in cash, cash equivalents and short-term investments at June 30, plus €767.1 million in net proceeds from its early-July offering, extending its cash runway into the fourth quarter of 2029. Abivax H1 Net Loss Widens; Plans Obefazimod NDA For Ulcerative Colitis By End Of 2026
• Positive Sentiment: The completed buyback of royalty certificates materially reduces a potential royalty overhang and leaves Abivax debt-free, improving financial flexibility ahead of possible commercialization. The company also appointed Tim Kelly as chief technical officer to support manufacturing, quality and commercial-supply readiness. Abivax Presents Business Updates and First Half 2026 Financial Results
• Neutral Sentiment: Analysts maintain an average “Moderate Buy” rating, suggesting that Wall Street remains constructive on the company’s longer-term prospects, although the stock’s roughly $9 billion valuation depends heavily on the success and regulatory progress of obefazimod. Abivax Receives Average Rating of Moderate Buy
• Neutral Sentiment: Chris Rabbat will succeed Fabio Cataldi as chief medical officer. The leadership transition may support continued clinical and regulatory execution, but it also introduces an additional management change as Abivax approaches key development milestones. Abivax Announces Chief Medical Officer Succession
• Negative Sentiment: Abivax reported a quarterly loss of $1.71 per share, substantially worse than the $0.92 consensus estimate. Although quarterly revenue of $1.37 million exceeded the $0.80 million forecast, the wider-than-expected loss and continued clinical-stage cash burn are weighing on sentiment. Abivax Releases Earnings Results and Misses EPS Expectations

Analyst Upgrades and Downgrades

A number of research firms recently commented on ABVX. Morgan Stanley reissued an “overweight” rating and issued a $180.00 price target on shares of Abivax in a research report on Friday, July 24th. Piper Sandler raised their price target on shares of Abivax from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Guggenheim restated a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Wedbush decreased their price objective on shares of Abivax from $140.00 to $118.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Wolfe Research set a $136.00 target price on shares of Abivax in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $156.69.

Institutional Investors Weigh In On Abivax

A number of hedge funds have recently made changes to their positions in the business. Versant Capital Management Inc purchased a new position in shares of Abivax in the 2nd quarter worth about $30,000. GHP Investment Advisors Inc. increased its holdings in Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after buying an additional 140 shares during the last quarter. Assetmark Inc. increased its holdings in Abivax by 41.5% during the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock worth $99,000 after buying an additional 260 shares during the last quarter. Troluce Capital Advisors LLC bought a new stake in Abivax in the second quarter worth about $133,000. Finally, Clearstead Advisors LLC bought a new stake in Abivax in the fourth quarter worth about $138,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Price Performance

The stock has a market capitalization of $8.58 billion, a PE ratio of -18.86 and a beta of 0.96. The stock’s 50 day simple moving average is $120.76 and its two-hundred day simple moving average is $117.67.

Abivax Company Profile

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.